Yacine Maringer

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Journal: The Lancet. Haematology

Published: September 18, 2025

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

Journal: Journal for immunotherapy of cancer

Published: March 20, 2025

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Journal: Frontiers in immunology

Published: August 18, 2024

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Journal: Frontiers in oncology

Published: July 02, 2024

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Journal: Frontiers in oncology

Published: May 31, 2024

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Journal: Frontiers in oncology

Published: January 08, 2024

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: August 28, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Journal: Nature communications

Published: June 14, 2023

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome.

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome.

Journal: Viruses

Published: February 12, 2023

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.

Journal: Blood cancer discovery

Published: February 03, 2023

Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination.

Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination.

Journal: Science immunology

Published: November 01, 2022

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome.

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome.

Journal: Cancers

Published: August 08, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026